Please wait while the formulary information is being retrieved.
SKYRIZI (risankizumab-rzaa)
- Moderate to severe plaque psoriasis
75 mg/0.83 mL subcutaneous syringe
- Inject 150 mg as 2 consecutive 75 mg injections by subcutaneous routeevery 12 weeks in the abdomen, thigh, or upper arm; rotate sites
Moderate to severe plaque psoriasis
- Inject 150 mg as 2 consecutive 75 mg injections by subcutaneous routeonce in the abdomen, thigh, or upper arm; rotate sites
- Inject 150 mg as 2 consecutive 75 mg injections by subcutaneous routeonce at weeks 0 and 4 in the abdomen, thigh, or upper arm; rotate sites
- Inject 150 mg as 2 consecutive 75 mg injections by subcutaneous routeevery 12 weeks in the abdomen, thigh, or upper arm; rotate sites
- Inject 1.66 milliliters (150 mg) as 2 consecutive 75 mg injections bysubcutaneous route once in the abdomen, thigh, or upper arm; rotate sites
- Inject 1.66 milliliters (150 mg) as 2 consecutive 75 mg injections bysubcutaneous route every 12 weeks in the abdomen, thigh, or upper arm; rotate sites
- Inject 1.66 milliliters (150 mg) as 2 consecutive 75 mg injections bysubcutaneous route once at weeks 0 and 4 in the abdomen, thigh, or upper arm; rotate sites
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- None
Severe
Moderate
- None
- Active tuberculosis
Contraindicated
- Inactive tuberculosis
- Severe infection
Severe
Moderate
- None
SKYRIZI (risankizumab-rzaa)
- Moderate to severe plaque psoriasis
- None
- Dermatophytosis
- Fatigue
- Headache disorder
- Injection site sequelae
- Upper respiratory infection
More Frequent
Severe
Less Severe
- Infection
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Cellulitis
- Herpes zoster
- Osteomyelitis
- Pneumonia
- Sepsis
Less Severe
- Folliculitis
- Urticaria
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Risankizumab-rzaa
Safety and effectiveness have not been established in pediatric patients.
- 1 Day – 18 Years
- Safety and effectiveness have not been established in pediatric patients.
Risankizumab-rzaa
- Severity Level:
2
- Additional Notes: Insufficient human data available.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Risankizumab-rzaa
Insufficient data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Moderate to severe plaque psoriasis | |
| L40.0 | Psoriasis vulgaris |
| L40.9 | Psoriasis, unspecified |
| 0-9 | A-Z |
|---|---|
| L40.0 | Psoriasis vulgaris |
| L40.9 | Psoriasis, unspecified |
Formulary Reference Tool